Perspectives on HCV Cure
- 21 Downloads
The development of interferon-free cures for hepatitis C has revolutionized the treatment of patients chronically infected with the hepatitis C virus. Since 2010, ten new curative regimens have been introduced into clinical practice. These new regimens have delivered cure rates in excess of 95% in as little as 8–10 weeks on therapy. Never before has there been an absolute cure for a chronic viral disease. This medical breakthrough has been made possible by the commitment of scientists and clinicians from both academia and industry working toward a common goal. Because of the availability of these curative regimens, it is now possible to contemplate eliminating HCV as a global public health problem as outlined by the World Health Organization. This perspective will give a brief commentary of the achievements and future possibilities provided by direct-acting antiviral interferon-free HCV cure therapies.
KeywordsHCV cure therapies HCV elimination Hepatitis C Hepatitis C virus Interferon-free HCV therapy WHO HCV elimination program
Compliance with Ethical Standards
Conflict of Interest: Author is co-founder, Chief Scientific Officer and shareholder of Arbutus Biopharma, Inc. Author is a consultant for Gilead Sciences, Inc. Author was an employee of Pharmasset Inc. and Gilead Sciences Inc.
Ethical Approval: This article does not contain any studies with human participants or animals performed by any of the authors.
- 3.Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K, HCV Research UK (2016) Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64(6):1224–1231CrossRefGoogle Scholar
- 10.Sonali P, Cotter T, Sandikci B, Couri T, Little EC, Sundaram V, Bodzin A, Charlton M (2018) Increasing utilization and excellent early outcomes following liver transplant of HCV viremic donors into HCV positive and negative recipients. The liver meeting 2018, San Francisco, CA, November 9–13Google Scholar
- 11.Sulkowski M, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard D, Symonds W, Subramanian GM, McHutchinson JG, Rodriguez-Torres M, Deiterich D (2014) Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312(4):353–361CrossRefGoogle Scholar
- 13.Geneva: World Health Organization (2017) Global health report, 2017Google Scholar
- 17.Online HC (2018) Cost and access to direct-acting antiviral agents. https://www.hepatitisc.uw.edu/pdf/evaluation-treatment/cost-access-medications/core-concept/all. Accessed 29 Nov 2018